Skip to content

Steven Fruchtman

Steven Fruchtman

Company: Onconova Therapeutics

Job title: President & CEO


Rigosertib: Targeting the Ras+ Pathway and Clinical Trials in MDS and Beyond 10:30 am

Rigosertib is a Ras mimetic; but how does it target constitutively activated pathways in cancer? What is the role of Ras+ in myelodysplastic syndromes with an introduction of clinical trials underway; focusing on pivotal Ph 3 Trials in myelodysplastic syndromes. The Rasopathies are a group of genomic Ras+ driven disorders in childhood, requiring innovative approaches…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.